Living with mesothelioma. A literature review
Corresponding Author
S. MOORE msc, bsc (hons), rn, lung cancer nurse specialist
Royal Marsden NHS Foundation Trust, Surrey
Sally Moore, Royal Marsden NHS Foundation Trust, Downs Road Sutton, Surrey SM2 5PT, UK (e-mail: [email protected]).Search for more papers by this authorL. DARLISON bsc (hons), rn, fetc, consultant nurse
The University Hospitals of Leicester, Leicester
Search for more papers by this authorA.M. TOD phd, msc, mmedsci, rn, principle research fellow
Centre for Health and Social Care Research, Sheffield Hallam University, Collegiate Campus, Sheffield, UK
Search for more papers by this authorCorresponding Author
S. MOORE msc, bsc (hons), rn, lung cancer nurse specialist
Royal Marsden NHS Foundation Trust, Surrey
Sally Moore, Royal Marsden NHS Foundation Trust, Downs Road Sutton, Surrey SM2 5PT, UK (e-mail: [email protected]).Search for more papers by this authorL. DARLISON bsc (hons), rn, fetc, consultant nurse
The University Hospitals of Leicester, Leicester
Search for more papers by this authorA.M. TOD phd, msc, mmedsci, rn, principle research fellow
Centre for Health and Social Care Research, Sheffield Hallam University, Collegiate Campus, Sheffield, UK
Search for more papers by this authorAbstract
MOORE S., DARLISON L. & TOD A.M. (2010) European Journal of Cancer CareLiving with mesothelioma. A literature review
Mesothelioma is an asbestos-related cancer that affects mainly the pleura. World-wide incidence is increasing and set to rise for some time particularly in developing countries. Mesothelioma is uniformly fatal and often associated with difficult symptoms. The purpose of this review is to identify what is known about the experience of people living with mesothelioma. A literature search identified 13 papers covering qualitative studies, patient-reported quality of life data collected as part of a clinical trial, symptoms and survey of patients and carers. The findings suggest the impact of mesothelioma is multidimensional on: physical symptoms (especially pain, breathlessness, fatigue, cough, sleep disturbance, appetite loss and sweating), emotional functioning (anxiety, depression, fear and isolation), social consequences (changes in roles and relationships) and interventions (the necessity of frequent anti-cancer treatments and admissions for symptom control). The impact on family members is significant also. Although limited, these findings provide an important insight into the impact of mesothelioma on patients and family members and suggest areas where service provision may fail to meet their needs. Finally, the review highlights an urgent need for further research to more fully understand the experience of living with mesothelioma and identify the specific needs of patients and family members.
REFERENCES
- Antman K., Shemin R., Ryan L., Klegar K., Osteen R., Herman T., Lederman G. & Corson J. (1988) Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965–1985. Journal of Clinical Oncology 6, 147–153.
- Bakwaj S. & Lee B. (2005) Case 23. Difficult pain in a patient with mesothelioma. European Journal of Palliative Care 12, 237–238.
- Bottomley A., Gaafa R., Manegold C., Burgers S., Coens C., Legrand C., Vincent M., Giaccone G. & Van Meerbeeck J. (2006) Short-term treatment-related symptoms and quality of life: results from an international randomised phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Cananda, Intergroup study. Journal of Clinical Oncology 24, 1435–1442.
- Bottomley A., Coens C., Eficace F., Gaafar R., Manegold C., Burgers S., Vincent M., Legrand C. & Van Meerbeck J.P. (2008) Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. Journal of Clinical Oncology 25, 5770–5776.
- Boutin C., Schlesser M., Frenay C. & Astoul P. (1998) Malignant pleural mesothelioma. European Respiratory. Journal 12, 972–981.
- British Lung Foundation (BLF) Survey of Mesothelioma Patients and their Carers. BLF, London. Available at: http://www.lunguk.org/Resources/British%20Lung%20Foundation/Survey%20of%20mesothelioma%20patients%20and%20their%20carers%20FINAL%20(complete).pdf (8/3/09).
- British Thoracic Society (2007) Statement on Malignant Mesothelioma in the UK. British Thoracic Society, London.
- Cancer Research UK (2007) UK Cancer incidence statistics for common cancers. Available at: http://info.cancerresearchuk.org/cancerstats/incidence/commoncancers/?a=5441 (01/02/09).
- Cancer Research UK (2008) UK Cancer mortality statistics for common cancers. Available at: http://info.cancerresearchuk.org/cancerstats/mortality/cancerdeaths/ (01/02/09).
- Chahinian A.P., Thomas M.D., Pajak F., Holland J.F., Norton L., Ambinder R.M. & Mandel E.M. (1982) Diffuse malignant mesothelioma: prospective evaluation of 69 patients. Annals of Internal Medicine 96, 746–755.
- Chapman E., Hughes D., Landy A., Whale J. & Saunders M. (2005) Challenging the respresentations of cancer pain: experiences of a multidisciplinary pain management group in a palliative care unit. Palliative & Supportive Care 3, 43–49.
- Clayson H., Seymour J. & Noble B. (2005) Mesothelioma from the patient's perspective. Hematology Oncology Clinics of North America 19, 1175–1190.
- Curran D., Sahmoud T., Therasse P., Van Meerbeeck J., Postmus P.E. & Giaccone G. (1998) Prognostic factors in patients with pleural mesothelioma: the European Organisation for Research and Treatment of Cancer experience. Journal of Clinical Oncology 16, 145–152.
- De Klerk N.H. & Musk A.W. (2002) Epidemiology of mesothelioma. In: Mesothelioma. (eds B.W. Robinson, P.A. Chahinian), pp. 39–50. Martin Dunitz, London.
- Department of Health (DOH) (2007) Mesothelioma Framework: Advice for the NHS on How to Organise Services for Malignant Pleural Mesothelioma (MPM) Patients to Improve Quality of Care across the Country. Gateway ref: 7907. DOH, London.
- Edwards J.G., Abrams K.R., Leverment J.N., Spyt T.J., Waller D.A. & O'Byrne K.J. (2000) Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 55, 731–735.
- Foss C. & Ellefsen B. (2002) The value of combining qualitative and quantitative approaches in nursing research by means of method triangulation. Journal of Advanced Nursing 40, 242–248.
- Hawley R., Monk A. & Wiltshire J. (2004) The mesothelioma journey. Unpublished report. University of Sydney.
- Herndon J.E., Green M.R., Chahinian A.P., Corson J.M., Suzuki Y. & Vogelzang N.J. (1998) Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113, 723–731.
- Hollen P.J., Gralla R.J., Liepa A.M., Symanowski J.T. & Rusthoven J.J. (2004) Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma. Cancer 101, 587–595.
- Hughes N. & Arber A. (2008) The lived experience of patients with pleural mesothelioma. International Journal of Palliative Nursing 14, 66–71.
- International Mesothelioma Interest Group (IMIG) (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 108, 1122–1128.
- Kazan-Allen L. (2005) Asbestos and mesothelioma: worldwide trends. Lung Cancer 49, 53–58.
- Lebovits A.H., Chahinian A.P., Gorzynski J.G. & Holland J.C. (1981) Psychological aspects of asbestos-related meosthelioma and knowledge of high risk for cancer. Cancer Detection and Prevention 4, 181–184.
- Lebovits A.H., Chahinian A.P. & Holland J.C. (1983) Exposure to asbestos: psychological responses of mesothelioma patients. American Journal of Industrial Medicine 4, 459–466.
- Montanaro F., Bray F., Gennaro V., Merler E., Tyczynski J.E., Parkin D.M. & the ENCR working Group (2003) Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes and Control 14, 791–803.
- Moore S., Teehan C., Cornwall A., Ball K. & Thomas J. (2008) ‘Hands of Time’: the experience of establishing a support group for people affected by mesothelioma. European Journal of Cancer Care 17, 585–592.
- Muers M.F., Stephens R.J., Fisher P., Darlison L., Higgs C.M.B., Lowry E., Nicholson A.G., O'Brien M., Peake M., Rudd R., Snee M., Steele J., Girling D.J., Nankivell M., Pugh C. & Parmar M.K.B. on behalf of the MS01 trial management group (2008) Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 371, 1685–1694.
-
National Cancer Research Institute (NCRI) (2006) Lung Cancer Research in the UK. London. NCRI.
10.1016/S0140-6736(08)60727-8 Google Scholar
- Nowak A.K., Stockler M.R. & Byrne M.J. (2004) Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity and results of using the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. Journal of Clinical Oncology 22, 3172–3180.
- O'Brien M.E.R., Watkins D., Ryan C., Priest K., Corbishley C., Norton A., Ashley S., Rowell N. & Sayer R. (2006) A randomised trail in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Annals of Oncology 17, 270–275.
- O'Byrne K.J., Edwards J.G. & Waller D.A. (2004) Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer 45, S45–48.
- Patel S.N. & Kettner N.W. (2005) Malignant pleural mesothelioma: a case report. Journal of Manipulative and Physiological Therapeutics 28, 724–729.
- Ruffie P., Feld R., Minkin S., Cormier Y., Boutan-Laroze A., Ginsberg R., Ayoub J., Shepherd F., Evans W.K., Figuerdo A., Pater J.L., Pringle J.F. & Kreisman H. (1989) Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. Journal of Clinical Oncology 7, 1157–1168.